Jun 3, 2021 · Acute myeloid leukemia is a genetically heterogeneous hematologic malignancy; approximately 20% of AML harbors a mutation in the isocitrate dehydrogenase (IDH) genes, …

Oct 2, 2023 · Somatic mutations in isocitrate dehydrogenase (IDH) genes occur frequently in adult acute myeloid leukemia (AML) and less commonly in pediatric AML. The objective of this study …

Apr 10, 2024 · In this review, we outline the role of IDH mutations in malignant transformation, focus in on a novel group of targeted therapeutic agents directed toward IDH1 - and IDH2 …

Mutations in the IDH1 gene at position R132 coding for the enzyme cytosolic isocitrate dehydrogenase are known in glioma and have recently been detected also in acute myeloid …

Feb 3, 2023 · IDH1 R132 and IDH2 R172 positive MRD at HSCT is associated with inferior outcomes. Somatic mutations in the isocitrate dehydrogenase 1 and 2 genes (IDH1 and IDH2) …

With a combined prevalence of approximately 20%, mutations in isocitrate dehydrogenase 1 (IDH1) and IDH2 are among the most recurrent genetic abnormalities in newly diagnosed …

Apr 20, 2022 · The combination of ivosidenib — an inhibitor of mutant isocitrate dehydrogenase 1 (IDH1) — and azacitidine showed encouraging clinical activity in a phase 1b trial involving …

AML patients with IDH1 mutations had inferior overall survival compared to patients without the mutations (hazard ratio 1.17, 95% CI: 1.02–1.36). Additionally, in CN-AML patients, IDH1 …

Mutations in IDH1 or IDH2 are detected in approximately 20% of patients with acute myeloid leukemia (AML) and induce amino acid changes in conserved residues resulting in …

Jun 2, 2018 · Ivosidenib (AG-120) is an oral, targeted, small-molecule inhibitor of mutant IDH1. We conducted a phase 1 dose-escalation and dose-expansion study of ivosidenib …